Strategic Initiative

Slingshot members are tracking this corporate initiative:

Gilead(GILD) and Galapagos(GLPG) Enter Collaboration

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details
Galapagos will receive a $3.95 billion upfront payment and a $1.1 billion equity investment from Gilead. Galapagos will use the proceeds to expand and accelerate its research and development programs. Gilead will receive an exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe. In addition, Gilead and Galapagos have agreed to amend certain terms in the agreement governing filgotinib, the candidate being advanced for rheumatoid arthritis and other inflammatory diseases to provide a broader commercialization role for Galapagos in Europe.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jul 14, 2019
Projected Implementation:
Q3, 2019
Relevance Tracked Until:
Q4, 2019
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Filgotinib, Glpg1690